Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules

Oncology Research

Volumn 16, Issue 3, 2006, Pages 143-156

  Tempestini, Alessio ^a   Caciagli, Barbara ^a   Morganti, Maria ^a   Witort, Ewa ^a   Nobili, Stefania ^a   Papucci, Laura ^a   Schiavone, Nicola ^a   Donnini, Martino ^a   Landini, Ida ^a   Lapucci, Andrea ^a   Perna, Federico ^a   Lulli, Matteo ^a   Mazzei, Teresita ^a   Sobrero, Alberto ^b   Mini, Enrico ^a   Capaccioli, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

5 Fluorouracil; Colon carcinoma; Drug administration schedule; Drug resistance; Gene expression; Tumor cell lines

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PROTEIN BCL 2; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ARTICLE; CARCINOMA CELL; CELL GROWTH; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG RESISTANCE; ENZYME ANALYSIS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 33747304588     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981189     Document Type: Article

References (36)

1. Grem, J. L. 5-Fluoropyrimidines. In: Chabner, B. A.; Longo, D. L., eds. Cancer chemotherapy and biotherapy: Principles and practice. Philadelphia: Lippincott Williams & Wilkins; 2001:185-264.
2. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5):330-338; 2003.
3. Cao, S.; Frank, C.; Rustum, Y. M. Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma. J. Natl. Cancer Inst. 88(7):430-436; 1996.
4. Aschele, C.; Sobrero, A.; Faderan, M. A.; Bertino, J. R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:1855-1864; 1992.
5. Harstrick, A.; Gonzales, A.; Schleucher, N.; Vanhoefer, U.; Lu, K.; Formento, J. L.; Milano, G.; Wilke, H.; Seeber, S.; Rustum, Y. Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: Biochemical mechanism of resistance. Anticancer Drugs 9:625-634; 1998.
6. Yeh, K. H.; Yeh, S. H.; Hsu, C. H.; Wang, T. M.; Ma, I. F.; Cheng, A. L. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br. J. Cancer 83(11):1510-1515; 2000.
7. Sobrero, A. F.; Aschele, C.; Guglielmi, A. P.; Mori, A. M.; Melioli, G. G.; Rosso, R.; Bertino, J. R. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst. 85(23):1937-1944; 1993.
8. Mori, A.; Bertoglio, S.; Guglielmi, A.; Aschele, C.; Bolli, E.; Tixi, L.; Rosso, R.; Sobrero, A. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother. Pharmacol. 33(2):179-180; 1993.
9. Tralongo, P.; Di Mari, A.; Scibilia, G.; Bosco, V.; Giudice, A.; Respini, D.; Failla, G. Prolonged 5-fluorouracil infusion in patients with metastatic colon cancer pretreated with bolus schedule of the same agent. Anticancer Res. 15(2):635-638; 1995.
10. Falcone, A.; Allegrini, G.; Lencioni, M.; Pfanner, E.; Brunetti, I.; Cianci, C.; Galli, C.; Masi, G.; Antonuzzo, A.; Conte, P. Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: A phase II study. Cancer Chemother. Pharmacol. 44(2):159-163; 1999.
11. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16(1):301-308; 1998.
12. Sobrero, A. F.; Aschele, C.; Bertino, J. R. Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation. J. Clin. Oncol. 15:368-381; 1997.
13. Gorlick, R.; Banerjee, D. Fluoropyrimidine resistance in colon cancer. Expert Rev. Anticancer Ther. 2:409-416; 2002.
14. Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H. J.; Leichman, C. G.; Leichman, L.; Diasio, R. B.; Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6(4):1322-1327; 2000.
15. Violette, S.; Poulain, L.; Dussaulx, E.; Pepin, D.; Faussat, A. M.; Chambaz, J.; Lacorte, J. M.; Staedel, C.; Lesuffleur, T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer 98(4):498-504; 2002.
16. Maxwell, P. J.; Longley, D. B.; Latif, T.; Boyer, J.; Allen, W.; Lynch, M.; McDermott, U.; Harkin, D. P.; Allegra, C. J.; Johnston, P. G. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 63:4602-4606; 2003.
17. Clarke, P. A.; George, M. L.; Easdale, S.; Cunningham, D.; Swift, R. I.; Hill, M. E.; Tait, D. M.; Workman, P. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res. 63:6855-6863; 2003.
18. Mariadason, J. M.; Arango, D.; Shi, Q.; Wilson, A. J.; Corner, G. A.; Nicholas, C.; Aranes, M. J.; Lesser, M.; Schwartz, E. L.; Augenlicht, L. H. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63:8791-8812; 2003.
19. Schmidt, W. M.; Kalipciyan, M.; Dornstauder, E.; Rizovski, B.; Steger, G. G.; Sedivy, R.; Mueller, M. W.; Mader, R. M. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int. J. Cancer 112:200-212; 2004.
20. Kim, H. K.; Choi, I. J.; Kim, H. S.; Kim, J. H.; Kim, E.; Park, I. S.; Chun, J. H.; Kim, I. H.; Kim, I. J.; Kang, H. C.; Park, J. H.; Bae, J. M.; Lee, J. S.; Park, J. G. DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem. Biophys. Res. Commun. 316:781-789; 2004.
21. Tompkins, W. A.; Watrach, A. M.; Scemale, J. D.; Schulz, R. M.; Harris, J. A. Cultural and antigenic properties of newly established cell strains derived from adenocarcinoma of the human colon and rectum. J. Natl. Cancer Inst. 52:1101-1110; 1974.
22. Schiavone, N.; Papucci, L.; Lucani, P.; Lapucci, A.; Donnini, M.; Capaccioli, S. Induction of apoptosis and mitosis inhibition by degraded DNA lipotransfection mimicking genotoxic drug effects. Biochem. Biophys. Res. Commun. 270:406-414; 2000.
23. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; Mcmahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric citotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1990.
24. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159; 1987.
25. Mini, E.; Biondi, C.; Morganti, M.; Napoli, C.; Mazzoni, P.; Cianchi, F.; Tonelli, F.; Cortesini, C.; Capaccioli, S.; Ficari, F.; Quattrone, A.; Rossi, S.; Mazzei, T. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol. Res. 11:437-445; 1999.
26. Lokich, J.; Anderson, N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann. Oncol. 8(1):15-25; 1997.
27. van Laar, J. A. M.; van der Wilt, C. L.; Rustum, Y. M.; Noordhuis, P.; Smid, K.; Pinedo, H. M.; Peters, G. J. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin. Cancer Res. 2:1327-1333; 1996.
28. Ford, H. E.; Mitchell, F.; Cunningham, D.; Farrugia, D. C.; Hill, M. E.; Rees, C.; Calvert, A. H.; Judson, I. R.; Jackman, A. L. Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin. Cancer Res. 8:103-109; 2002.
29. Saini, A.; Norman, A. R.; Cunningham, D.; Chau, I.; Hill, M. E.; Tait, D.; Hickish, T.; Iveson, T.; Lofts, F.; Jodrell, D.; Ross, P. J.; Oates, J. R. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br. J. Cancer 88(12):1859-1865; 2003.
30. Raymond, E.; Lawrence, R.; Izbicka, E.; Faivre, S.; Von Hoff, D. D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res. 4(4):1021-1029; 1998.
31. Cunningham, D.; Pyrhonen, S.; James, R. D.; Punt, C. J.; Hickish, T. F.; Heikkila, R.; Johannesen, T. B.; Starkhammar, H.; Topham, C. A.; Awad, L.; Jacques, C.; Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138):1413-1418; 1998.
32. Rougier, P.; Van Cutsem, E.; Bajetta, E.; Niederle, N.; Possinger, K.; Labianca, R.; Navarro, M.; Morant, R.; Bleiberg, H.; Wils, J.; Awad, L.; Herait, P.; Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138):1407-1412; 1998.
33. Fuchs, C. S.; Moore, M. R.; Harker, G.; Villa, L.; Rinaldi, D.; Hecht, J. R. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21(5):807-814; 2003.
34. Rougier, P.; Lepille, D.; Bennouna, J.; Marre, A.; Ducreux, M.; Mignot, L.; Hua, A.; Mery-Mignard, D. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann. Oncol. 13(10):1558-1567; 2002.
35. Maindrault-Goebel, F.; Louvet, C.; Andre, T.; Carola, E.; Lotz, J. P.; Molitor, J. L.; Garcia, M. L.; Gilles-Amar, V.; Izrael, V.; Krulik, M.; de Gramont, A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur. J. Cancer 35(9):1338-1342; 1999.
36. Bajetta, E.; Beretta, E.; Di Bartolomeo, M.; Cortinovis, D.; Ferrario, E.; Dognini, G.; Toffolatti, L.; Buzzoni, R. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. Oncology 66:132-137; 2004.